latest news releases from the newsroom
LTX-Credence Introduces New DC and Power Option for X-Series Test Systems
MILPITAS, Calif., Dec. 16, 2008 (GLOBE NEWSWIRE) -- LTX-Credence Corporation (Nasdaq:LTXC), a global provider of focused, cost-optimized ATE solutions, today announced the addition of its Quad Floating VI (QFVI) option for its X-Series test platform. The QFVI addresses critical requirements for cost effective testing of advanced power management and automotive applications, such as battery charging and management, high side and full bridge switch networks and a broad range of brake, airbag, ignition and motor controllers.
Arasan Chip Systems, Inc.
Arasan Chip Systems First to Provide End-to-End Solution with MIPI D-PHY IP
SAN JOSE, Calif., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Arasan Chip Systems, Inc., "Arasan" a leader in Intellectual Property (IP) solutions - IP cores, Verification IP (VIP), Software Drivers and Stacks and Hardware Solutions, announced the immediate availability of the silicon-proven Mobile Industry Processor Interface (MIPI(sm)) D-PHY IP, for use with Display Serial Interface (DSI), Camera Serial Interface (CSI), and UniPro(sm) protocol. As a leading provider of mobile IP, Arasan continues to strengthen its strategic mobile initiative by expanding the MIPI IP portfolio with physical analog IP, therefore enabling a complete and comprehensive MIPI solution.
Nymox Pharmaceutical Corporation
Nymox Releases New Study Data From U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep for Men Given Nymox Drug
HASBROUCK HEIGHTS, N.J., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced new results from a recently completed multi-center U.S. clinical study of NX-1207, the Company's innovative investigational drug for benign prostatic hyperplasia (BPH). The evidence indicates that NX-1207 can markedly reduce the incidence of nocturia, a particularly bothersome symptom of nighttime urination associated with BPH. After 90 days, subjects treated with a therapeutic dose of NX-1207 had a mean 49% reduction in nocturia symptoms, which was statistically significant compared to baseline (p less than .001).
Bioheart, Inc. Announces Plans to Divest Non-Core Products to Increase Focus On Heart Failure Treatments
SUNRISE, Fla., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today that it is planning to spin out or sell off its interest in several non-core technology platforms in order to intensify its strategic focus on the treatment of patients suffering from heart failure. Bioheart holds the rights to multiple patents and patents pending related to these non-core technologies as well as proprietary know-how and trade secrets. Animal data supporting the proof of concept for some of these technologies is also available from the Company.
Ad hoc: Jerini AG: Jerini Receives Request for Transfer of Minority Shareholders' Shares in Jerini AG to Shire Deutschland Investments GmbH
BERLIN, Germany, Dec. 16, 2008 (GLOBE NEWSWIRE) -- The Management Board of Jerini AG (FSE:JI4) has received a formal request, according to section 327a of the German Stock Corporation (AktG), from Shire Deutschland Investments GmbH, an indirect subsidiary of Shire plc, (formerly Shire Limited) with registered offices in Frankfurt am Main, to pass a resolution at Jerini's General Shareholders' Meeting calling for the transfer of shares held by Jerini's minority shareholders to Shire Deutschland Investments GmbH (so-called "Squeeze Out"). As compensation, minority shareholders will receive payment of adequate cash compensation from Shire Deutschland Investments GmbH.